Can new international and European standards increase patients’ safety by reducing the negative impact of external factors on in vitro diagnostic test results, thus ensuring that patients obtain diagnoses that are as objective as possible? Can these standards help to decrease uncertainty for industry players during the discovery, research, development and clearance process of new IVDs?
The event organised by BBMRI-ERIC and SPIDIA4P at the European Parliament gave the opportunity to all actors working in the field of personalised medicine, in vitro diagnostics and standardisation to discuss the main regulatory challenges during the discovery and development of new biomarkers for in vitro diagnostic medical devices (IVDs) and personalised medicine solutions.
Read more about this event here.